Genotype and drug susceptibility phenotype analysis of carbapenem-resistant Enterobacter cloacae in Taizhou area
10.13602/j.cnki.jcls.2025.01.02
- VernacularTitle:台州地区耐碳青霉烯类阴沟肠杆菌的基因型和药敏表型分析
- Author:
Haohao LI
1
;
Donglian WANG
;
Qingxin SHI
;
Sufei YU
;
Qingfeng YU
;
Yingying CAI
Author Information
1. 浙江省台州医院检验科,浙江 台州 317000;台州恩泽医疗中心(集团)恩泽医院检验科,浙江 台州 318000;台州市系统医学与精准诊治重点实验室,浙江 台州 317000
- Publication Type:Journal Article
- Keywords:
Enterobacter cloacae;
carbapenem resistance;
genotype;
enzyme type
- From:
Chinese Journal of Clinical Laboratory Science
2025;43(1):7-12
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the distribution of carbapenem-resistant genes and their drug susceptibility in vitro on carbapen-em-resistant Enterobacter cloacae(CRECC)in Taizhou area,and provide evidence for effective anti-infective treatment in clinical prac-tice.Methods Forty-seven strains of CRECC isolated from Enze Hospital,Taizhou Enze Medical Center(Group)and Luqiao Reha-bilitation Hospital during January 2015 and November 2022 were retrospectively analyzed.The enzyme types and resistance genes of carbapenemase were detected by the NG-Test Carba 5 and Carba-R Xpert,respectively,and the susceptibility of CERCC to common drugs was tested in vitro.Results Among 47 strains of CRECC,27 were detected to produce carbapenemase,including 24 producing New Delhi metallo-β-lactamase(NDM)type,1 producing both Klebsiella pneumoniae carbapenemase(KPC)and NDM types,and 2 producing imipenemase(IMP)type.One strain belonged to NDM genotype but no NDM enzyme type was detected.The CRECC strains had the highest sensitivity to polymyxin B(95.7%),followed by tigecycline(93.6%),fosfomycin(61.7%),and ceftazidime/avibac-tam(40.4%).In addition,the CRECC strains producing carbapenemase were more sensitive to polymyxin B,fosfomycin and aztreo-nam than those without producing carbapenemase.Conclusion The CRECC strains in Taizhou area are mainly NDM type,which has high sensitivity to polycolistin B,tigecycline and fosfomycin.NG-Test Carba 5 can not cover some strains that do not produce carbapen-emase or carry mutations in carbapenemase.
